What does this research mean for the field?

Prior exposure to immune checkpoint inhibitors is associated with poorer local control outcomes following near-infrared photoimmunotherapy in patients with recurrent or metastatic head and neck cancer. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To assess how the timing and treatment sequence of immune checkpoint inhibitors affect clinical outcomes in patients receiving near-infrared photoimmunotherapy for recurrent or metastatic head and neck cancer.

September 3, 2026International Journal of Clinical OncologyOpen Access

Clinical outcomes of near-infrared photoimmunotherapy according to immune checkpoint inhibitor timing and treatment sequence: a multicenter retrospective study

View Full Paper

Ask AI

Bookmark

Authors

TMTakuma Makino SFShohei Fujimoto YOYorihisa Orita

Discussion

Member takes

Overview

Multicenter retrospective study reveals prior immune checkpoint inhibitor exposure impairs local control after photoimmunotherapy in head and neck cancer, highlighting sequencing importance.

Key Points

To assess how the timing and treatment sequence of immune checkpoint inhibitors affect clinical outcomes in patients receiving near-infrared photoimmunotherapy for recurrent or metastatic head and neck cancer.
Multicenter retrospective study analyzing 44 patients with 48 lesions receiving initial near-infrared photoimmunotherapy between January 2021 and March 2026.
Compared outcomes primarily based on prior immune checkpoint inhibitor exposure versus no prior exposure, alongside exploratory sequencing and timing evaluations.
Median local control was 174 days in the prior immune checkpoint inhibitor group versus 342 days in the unexposed group (overall median 253 days; log-rank P = 0.031).
Local progression developed in 69.2% of lesions with prior exposure compared to 37.1% without (P = 0.059), with an overall objective response rate of 60.0% and disease control rate of 93.3% in 45 evaluable lesions.
Median overall survival was 866 days, with exploratory analyses demonstrating that treatment sequence and drug timing may affect outcomes.

Cite This Study

Makino et al. (2026) studied this question.

synapsesocial.com/papers/6a993592636c6408cfa7ddaa https://doi.org/10.1007/s10147-026-03180-2

View Full Paper

Ask AI

Bookmark

September 3, 2026International Journal of Clinical OncologyOpen Access

Clinical outcomes of near-infrared photoimmunotherapy according to immune checkpoint inhibitor timing and treatment sequence: a multicenter retrospective study

View Full Paper

Ask AI

Bookmark

Authors

TMTakuma Makino SFShohei Fujimoto YOYorihisa Orita

Discussion

Member takes

Overview

Multicenter retrospective study reveals prior immune checkpoint inhibitor exposure impairs local control after photoimmunotherapy in head and neck cancer, highlighting sequencing importance.

Key Points

To assess how the timing and treatment sequence of immune checkpoint inhibitors affect clinical outcomes in patients receiving near-infrared photoimmunotherapy for recurrent or metastatic head and neck cancer.
Multicenter retrospective study analyzing 44 patients with 48 lesions receiving initial near-infrared photoimmunotherapy between January 2021 and March 2026.
Compared outcomes primarily based on prior immune checkpoint inhibitor exposure versus no prior exposure, alongside exploratory sequencing and timing evaluations.
Median local control was 174 days in the prior immune checkpoint inhibitor group versus 342 days in the unexposed group (overall median 253 days; log-rank P = 0.031).
Local progression developed in 69.2% of lesions with prior exposure compared to 37.1% without (P = 0.059), with an overall objective response rate of 60.0% and disease control rate of 93.3% in 45 evaluable lesions.
Median overall survival was 866 days, with exploratory analyses demonstrating that treatment sequence and drug timing may affect outcomes.

Cite This Study

Makino et al. (2026) studied this question.

synapsesocial.com/papers/6a993592636c6408cfa7ddaa https://doi.org/10.1007/s10147-026-03180-2

View Full Paper

Ask AI

Bookmark